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Summary The presence of soluble laminin fragments in urine of healthy subjects, patients with diabetes, and
patients with tumours was studied using sandwich immunoenzymometric assay technique. The form of urinary
laminin (ULN) fragments was dramatically different from that of intact laminin, so ULN could be detected
only by using monoclonal antibodies. Mean levels of ULN in lung tumour were significantly higher
(171 fig gram-' creatinine) than those in healthy subjects, patients with diabetes, patients with stomach
tumour, and patients with colon tumour (respectively 91, 92, 77 and 53 gig gram-' creatinine). Immunopurified
ULN fragments showed an apparent molecular mass of 42 KD on electrophoresis. This fragment was
recognised as being derived from the N-terminal region of laminin B2 chain, because the N-terminal residues
of ULN were found to be completely homologous to B2 chain. These data suggested that ULN was almost all
fragmented, consisted mainly of N-terminal domain of the B2 chain, and was suspected of a tumour-
associated protein fragments probably derived from basement membrane degraded proteolytically by tumour
cells. ULN, increased in tumour patients, could be a potential clinical marker for monitoring the turnover of
basement membrane in tumours.
Laminin, a large multidomain glycoprotein of the extracel-
lular matrix, has attracted much interest because of its
importance in the development and maintenance of cellular
organisation (Timpl et al., 1979; Beck et al., 1990). Important
cellular functions attributed to laminin include stimulation of
growth and neurite outgrowth promotion (Kleinman et al.,
1985). Recently it has been shown that laminin is synthesised
by various tumour cells (Albrechtsen et al., 1981). It has also
been found that laminin interacts preferentially with malig-
nant tumour cells via the specific laminin receptors exposed
on the cell surface and enhances the metastatic phenotype
and cell-surface protease activity (Albini et al., 1989; Ramos
et al., 1990; Terranova et al., 1982; Teale et al., 1988).
A soluble form of laminin, present in serum and other
body fluids, has been measured for monitoring patients with
several disorders (Kropf et al., 1988; Risteli et al., 1982;
Brocks et al., 1986; Wurz & Crombach, 1988). Some clinical
reports observed a significant elevation of serum laminin
levels in various tumour patients, and speculated on the
possible causes of the increase of laminin in serum as being
increased laminin synthesis or increased proteolytic degrada-
tion by the tumour cells (Brocks et al., 1986). It was also
reported that serum laminin consisted of intact molecules or
P1 fragments. Such P1 fragments are most resistant to pro-
teases, and consist of around 300 KD central domain of the
cross molecule with no terminal globular domains (Beck et
al., 1990; Brocks et al., 1986). The presence of laminin in rat
urine was first reported in 1985 (Jukkola et al., 1985), and
measurements of human urinary laminin (ULN) in preg-
nancy using a commercial radioimmunoassay (RIA) have
been performed (Wurz & Crombach, 1988). However, the
structural analysis of human ULN antigens and measurements
of ULN levels in several patients have not yet been per-
formed.
The present study was undertaken to describe the relation
between ULN levels and cancer stage, and to assess the
possible diagnostic value of ULN fragments in lung tumours.
We also describe how target ULN molecules were found to
be apparently about 42 KD fragments, degraded products
derived from N-terminal regions of the laminin B2 chain.
Materials and methods
Monoclonal antibodies
Human laminin, of nearly intact form, was purified from
fresh human placenta according to a previous method
(Wewer et al., 1983) with the following modifications. Briefly,
placenta was completely washed with phosphate buffered
saline (PBS) to remove residual blood; it was homogenised in
4 M NaCl, and laminin was extracted from the insoluble
residue with 0.5 M NaCl in 0.05 M Tris-HCl buffer, pH 7.0.
The extract was fractionated on a column of Bio-Gel A 1.5m
(BioRad Laboratories). Laminin eluted in the void volume
was further purified on a Mono-Q ion exchange column by a
fast protein liquid chromatography system (Pharmacia).
Then, purified laminin migrated as a single molecule under
non-reducing condition on 2% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) containing
0.5% agarose. Human fibrinogen (Sigma Chemical Co.) and
mouse tumour laminin (Boehringer Mannheim GmbH) were
used as molecular markers on electrophoresis. Anti-laminin
monoclonal antibodies (MoAbs) were produced by the stan-
dard hybridoma technology (Harlow & David, 1988).
Purified human laminin was used as an immunogen, antigen
for screening hybridomas, and immunoenzymometric assay
(IEMA) standard. Three cloned hybridomas that secreted
anti-laminin MoAbs (HLN5, HLN41, and HLN82) were
established. Each MoAb immobilised on agarose column
could bind human laminin specifically in placenta extracts, so
all of these MoAbs were recognised to be specific to human
laminin.
Immunoassay procedure
IEMA for laminin using two different MoAbs was construc-
ted and performed as follows: Antibody HLN5 or HLN41
was purified by protein A chromatography and labelled with
horseradish peroxidase (Boehringer Mannheim GmbH).
Ninety-six-well microplates, coated with HLN82 MoAb at
the antibody concentration of 10 jLg ml -, were blocked using
PBS containing 1% bovine serum albumin (BSA). One hun-
dred j.l of a standard laminin (0, 10, 20, 40, 80, 160, or
320 ng ml-') or a sample was added to each well. The plate
was incubated for 1 h at room temperature and washed with
PBS containing 0.1% Tween-20 (Wako Pure Chemical Inc.).
Then, 100 gil of a solution of HLN5 or HLN41 MoAb
labelled with peroxidase was added to each well, followed by
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incubation for 1 h at room temperature. Finally, 100 li of
5.5 mM o-phenylenediamine dihydrochloride (Sigma Chemical
Co.) soution was added as substrate and the mixture was left
for 15 min at room temperature, after which the enzyme
reaction was stopped by adding 100p1 of 1 M sulphuric acid.
The absorbance at 492 nm was measured in a Titertek Multi-
scan (Flow Laboratories). Serum laminin P1 levels were
determined by a commercially available RIA (Behring-
Hoechst) as described elsewhere in detail (Kropf et al., 1988;
Brocks et al., 1986). Serum samples for laminin IEMA were
prediluted 4-fold with PBS containing 1% BSA.
Student's t-test as well as the Mann and Whitney non-
parametric test were used in the analysis of ULN levels in the
control and patient populations. However, since both
Student's t and Man-Whitney tests resulted in identical P
values, data were expressed as one P value. Differences were
considered as significant below P = 0.05.
The molecular size of laminin antigens in a 1.8 ml serum
sample of the patient with lung tumour, whose serum laminin
level was extremely elevated, was determined by two different
IEMA formats and commercial RIA after molecular-sieve
chromatography on a 1.5 x 130 cm Ultrogel AcA44 (IBF
biotechnics) column, equilibrated with PBS. Further clinical
data of this patient with a lung tumour could not be
obtained.
Assay ofcreatinine in urine
A commercially available kit (Wako Pure Chemical Inc.)
based on the method of Jaffe (Bonsnes & Taussky, 1945) was
used according to the manufacturer's instructions to assay
creatinine in urine. Urinary creatinine determination was per-
formed simultaneously with IEMA for ULN, and the amount
of ULN was expressed per milligram ofcreatinine. Results of
ULN levels are given as mean ± s.d.
Clinicl specimens
For evaluation of ULN assay, we collected a total of 297
spot urine samples from healthy subjects (n = 84), patients
with diabetes mellitus (48), patients with stomach cancer (74),
patients with colon cancer (10), and patients with lung cancer
(81), which were diagnosed based on several clinical examina-
tions. All clinical examinations were performed before sample
collections. All the patients with diabetes used in this study
were untreated and without angiopathy. All of 165 patients
with pathologically and histologically proven stomach, colon,
and lung cancers, who had no previous treatment of chemo-
therapy and radiotherapy, were entered into this study. Urine
samples of tumour patients were collected before surgery.
In the additional clinical study, to evaluate the correlation
between excretion level of ULN and tumour stage, we per-
formed a detailed staging in 62 of 74 patients with stomach
cancer and in 27 of 81 patients with lung cancer who pro-
vided urine samples. These 89 cancer patients were staged at
the time of diagnosis after the urine samples were collected.
Histological classification of stomach tumour was based on
the General Rules for the Gastric Cancer Study in Surgery
and Pathology in Japan (Japanese Research Society for Gas-
tric Cancer, 1981). Stage of the lung tumour was classified
according to the TNM classification of UICC (UICC, 1987).
Sixty-two patients with stomach cancer were classified into
seven patients with stage I, eight patients with stage II, eight
patients with stage III, 27 patients with stage IV, and 12
patients with recurrent tumour. Twenty-seven patients with
lung cancer were classified into four patients with stage I, six
patients with stage II, four patients with stage III, nine
patients with stage IV, and four patients with recurrent
tumour. Metastases to distant sites were detected in one
patient with stage IV stomach cancer, two patients with
recurrent stomach cancer, and three patients with recurrent
lung tumours. Serum and urine samples from 74 patients
with stomach cancer and ten patients with colon cancer was
collected simultaneously, and laminin levels of these samples
were determined by using IEMA for laminin. One patient
with colon cancer and one patient with stomach cancer,
whose serum laminin levels were slightly and extremely
elevated respectively, were selected from these 84 tumour
patients. We measured laminin levels in a dilution series of
these two serum samples.
For evaluation of the correlation among values of two
IEMAs and commerical RIA, serum samples were collected
from 42 donors, whose clincal information could not be
obtained. The urine and serum samples were frozen without
preservatives at - 20°C until the analysis was performed.
Immunoblotting analysis
ULN was purified from seven liters of pooled urine sample
from several healthy subjects using HLN82 MoAb immobi-
lised on an agarose gel column. Bound material was eluted
with PBS containing 8 M urea and dialysed against PBS.
ULN was separated by 12.5% SDS-PAGE and then transfer-
red to an Immobilon-P polyvinylidine difluoride membrane
(Millipore Co.) electrophoretically. All samples were heated
at 100°C for 5 nin without reduction. The bound antigens
were immunostained with peroxidase-labelled HLN5 MoAb
and 4-chloro-1-naphthol substrate (Sigma Chemical Co.).
Another transferred antigen was also stained with Coomassie
Blue dye and cut out for amino-terminal amino acid sequenc-
ing with using an Applied Biosystems model 470 sequencer
on the Edman degradation method according to a previous
report (Matsudaira, 1987).
Results
Purified placental laminin has the molecular mass of about
650 KD (Figure 1, lane A), and seemed to migrate slightly
lower than mouse laminin with the molecular mass of 800 KD
(Figure 1, lane B) and higher than human fibrinogen with the
molecular mass of 330 KD (Figure 1, lane C). Immunoaffinity
chromatographical analysis using immobilised MoAbs
resulted in the corroborating antigenic specificity of them for
laminin. This laminin used for antigen proved to be so highly
purified that all MoAbs were identified to be laminin-specific,
and were found not to react with some other contaminants in
human placenta extracts.
In this study, we newly constructed two IEMAs based on
immobilised HLN82 MoAb. The 82-5 IEMA was performed
using labelled HLN5 MoAb, and the 82-41 IEMA was per-
formed with labelled HLN41 MoAb. The precision of these
two assays was evaluated by the assay of two samples of
normal serum ten times each in a continuous series (intra-
assay) or twice each time in ten consecutive assays (interas-
say). The assessment of intra-assay precision in the 82-5
IEMA and 82-41 IEMA gave CVs of 1.8% and 4.5% for a
concentration of about 60 ngml-', 6.4% and 6.9% for a
concentration of about 145.0ngml-', respectively. Then, the
assessment of interassay precision in the 82-5 IEMA and
82-41 IEMA gave CVs of 6.2% and 8.1% for a concentra-
tion of about 60 ng ml-, 7.4% and 8.7% for a concentration
of 145 ngml-', respectively. The standard curves and the
dilution curves for serum samples from healthy subject,
patient with colon tumour, and patient with stomach tumour
in the 82-5 IEMA are shown in Figure 2. The curves appear
to be parallel, indicating that the same immunoreactive sub-
stances was measured in the different dilution series. A very
similar result was obtained in the 82-41 IEMA using dilution
series of the same serum samples, and also in the 82-5 IEMA
using dilution series of several urine samples. We examined
the correlation between serum laminin levels for RIA and
serum levels for IEMA. Relatively positive correlations could
be found between values for RIA and values for the 82-5
IEMA (R = 0.68), and between values for RIA and values
for the 82-41 IEMA (R = 0.67). The 82-5 IEMA and the 82-41
IEMA showed almost the same levels of serum laminin, and
these values were correlated extremely well (R = 0.91). We
established the molecular size of immunoreactive laminin in
serum by molecular-sieve chromatograpahy (Figure 3), andURINARY LAMININ FRAGMENT INCREASED IN TUMOUR
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Figure 1 Analysis of human placental laminin. Isolated human
placental laminin used for immunogen (lane A), mouse tumour
laminin (lane B), and human fibrinogen (lane C) were electro-
phoresed simultaneously in a 2% SDS-PAGE containing 0.5%
agarose without reduction. Molecular weight of mouse laminin
(800 KD) and human fibrinogen (330 KD) are indicated on the
right.
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Figure 2 IEMA for laminin. Immobilised HLN82 MoAb and
labelled HLN5 MoAb was used in this IEMA format. Standard
curve (A) for laminin and dilution curves of serum samples from
healthy subject (A), patients with stomach tumour (0), and
patients with colon tumour (0) are shown. Serum samples were
originally diluted 4-fold with PBS containing 1% BSA. Serial
dilutions of pre-diluted sera are denoted above the curves.
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Figure 3 Characterisation of the size of laminin antigens in
serum of lung tumur patients by molecular-sieve chromatography
on a column of Ultrogel AcA44. Elution position of globular
proteins (human fibrinogen, y-globulin, BSA, ovalbumin, and
lysozyme) of known molecular mass, which used for calibration,
are indicated by arrows. Vo denotes the void volume of the
column. Laminin levels of these eluted fractions for the 82-5
IEMA ( * ), the 82-41 IEMA (---0---), and RIA
(A -) was measured to determine the elution position of
serum laminin. Laminin levels of the 82-5 IEMA and the 82-41
IEMA was expressed as ng per ml, and laminin P1 levels of RIA
was expressed as units per ml.
they appear to be relatively uniform in size with a molecular
weight between fibrinogen and y-globulin. No difference in
the molecular weight was observed between the serum of
several patients with cancer and in serum of healthy subjects
(unpublished observation). In 15 urine samples selected ran-
domly from 84 samples of healthy subjects, we attempted to
measure ULN levels by RIA, the 82-5 IEMA, and the 82-41
IEMA. The precise determinations of ULN levels could be
performed using the 82-5 IEMA predominantly, so we
selected this format for measurements of laminin levels in the
297 urine specimens.
To eliminate the effect of variability in the rate of water
excretion, urinary antigen concentrations were expressed in
jig gram-' creatinine, as previously established (Mattila et al.,
1988). The results of laminin measurements in all urine sam-
ples are represented in Figure 4. Mean ULN level in stomach
tumours was lower (74 ± 72 jLg gram-' creatinine) than that
in healthy subjects (91 ± 37) or that in diabetes (92 ± 62).
Mean ULN level in colon tumours was also lower (53 ± 40)
than that in healthy subjects or that in diabetes. Mean ULN
level in lung tumours was higher significantly (171 ± 126)
than that in healthy subjects (P <0.0001), that in diabetes
(P <0.001), that in stomach tumours (P <0.0001), or that
in colon tumours (P <0.0001). No significant difference was
detected between mean ULN levels in any two groups of
healthy subjects, patients with diabetes, patients with
stomach cancer and patients with colon cancer. Using a
cutoff point of 165jiggram-' creatinine, mean + 2 s.d. of
ULN levels in 84 healthy subjects, elevated levels of ULN
were present in 48% of 81 patients with lung cancers.
Distribution of ULN levels in 62 patients with stomach
cancer and in 27 patients with lung cancer could be classified
into stages. ULN levels were high in none (0%) of the seven
patients with stage I stomach cancer, none (0%) of the eight
patients with stage II stomach cancer, two (25%) of the eight
patients with stage III stomach cancer, two (7%) of the 27
patients with stage IV stomach cancer, and five (42%) of the
12 patients yWith recurrent stomach cancer. ULN levels were
high in one (25%) of the four patients with stage I lung
cancer, 2 (33%) of the six patients with stage II lung cancer,
two (50%) of the four patients with stage III lung cancer,
five (56%) of the nine patients with stage IV lung cancer, and
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Figure 4 ULN levels in healthy subjects, patients with diabetes,
and patients with tumours. ULN levels were expressed in
figgram'l urinary creatinine. The mean value ± s.d. of each
group is shown by a bar. Significant elevation of ULN levels in
lung tumours was assessed from statistical analysis (Student's
t-test or Mann-Whitney test, see text).
three (75%) of the four patients with recurrent lung cancer.
ULN levels were extremely high in all of six patients with
distant metastases. ULN levels in 74 stomach and ten colon
cancers were not correlated with serum laminin levels in them
(R = 0.03).
Immobilised HLN82 MoAb was presumed to bind ULN
molecules effectively and could be used for antigen isolation
on an agarose column. The target ULN molecule detected by
using the 82-5 IEMA was visualised with peroxidase-labelled
HLN5 MoAb, and the single immunostained band on the
membrane showed that the apparent molecular mass of
target ULN was about 42 KD (Figure 5). We also observed
that labelled HLN41 MoAb did not immunostain any pro-
tein on this membrane. We performed N-terminal amino acid
sequencing analysis of this 42 KD protein on another mem-
brane and clearly identified that this protein had 15 residues,
including two indeterminants (Met-Asp-Glu-Xaa-Thr-Asp-
Glu-Gly-Gly-Arg-Pro-Gln-Arg-Xaa-Met-) on its N-terminal
portion. The undefined residues of the sequences, indicated
by Xaa on the results, were expected to be Cys, Ser, or His,
which were in poor yields during the Edman cycle. These 15
amino acids seemed to be involved in the published N-
terminal end sequences (NH2-Glu-Ala-Ala-Met-Asp-Glu-
Cys-Thr-Asp-Glu-Gly-Arg-Pro-Gln-Arg-Cys-Met-; underlined
part was matched with obtained sequence of ULN fragments)
of mature laminin B2 chain polypeptide (Pikkarainen et al.,
1988).
Discussion
This study reported the development of useful IEMA using
immobilised HLN82 MoAb and labelled HLN5 MoAb, pos-
sible to determine not only serum laminin levels but also
ULN levels in several patients and normal individual.
Precision of IEMA was recognised to be acceptable, and
good linearity of standard curve and sample dilutions was
also observed in IEMA for laminin (Figure 2).
Many studies have already confirmed that clinical efficacy
of measurement of serum laminin P1 fragments consisted of
the central portion of the laminin cross (Kropt et al., 1988;
Brocks et al., 1986; Wurz & Crombach, 1988). However,
none of these studies demonstrated that ULN levels could be
determined reliably by RIA for laminin P1 fragments. Serum
laminin levels in 42 specimens selected randomly measured
using the 82-5 IEMA and the 82-41 IEMA were correlated
extremely well, and positive correlations were also observed
between commercial RIA and each of the IEMAs. The
molecular mass of immunoreactive serum laminin for two
IEMAs and RIA was shown to be similar in the molecular-
sieve chromatographical analysis (Figure 3). Then, we recog-
nised that serum laminin molecules detected specifically with
the 82-5 IEMA and the 82-41 IEMA are all identical, and
that these molecules in serum had almost the same anti-
genecity as laminin P1 fragments commonly measured using
commercial RIA. In urine samples of healthy subjects, no
significant levels of laminin were detected using the 82-41
IEMA or RIA. These data suggested that urine samples
ordinarily contained little or no amount of intact laminin or
P1 fragments, and that almost all of ULN fragments could be
detected directly only by the 82-5 IEMA.
ULN levels in lung tumours were significantly elevated
than ULN levels in healthy subjects, in diabetes, or in other
tumours. In addition, ULN levels in three patients with acute
pneumonia were not elevated (unpublished observation).
Therefore, this 82-5 IEMA for ULN seems to have a satis-
factory sensitivity for detecting lung tumours. Our results
indicate substantial differences between the percentages of
patients positive for ULN at stage I lung tumour and those
at stage IV lung tumour, so we expected a direct correlation
between stage of tumour and ULN level in tumour patients.
Moreover, the ULN test would indeed be primarily advan-
tageous for patients with resectable lung tumour (such as
stage I). Similar correlation was observed between ULN level
and disease stage also in the 62 patients with stomach cancer.
However, positives for ULN test were not present in early
stage stomach cancer, and increased ULN levels were oberved
mostly in recurrent stomach cancer. These data demonstrated
that whereas ULN level was a useful indicator of lung cancer
stage, it was apparently elevated only in recurrent stomach
cancer, so the ULN test may have no place in population
screening of stomach and colon tumours. Contrary to our
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Figure 5 Immunoblot analysis of ULN fragments isolated from
pooled normal urine samples using MoAbs. Crude ULN isolated
using immobilised HLN82 MoAb was further separated on
12.5% SDS-PAGE and transblotted to the PVDF membrane.
The membranes were stained with Coomassie Blue dye, and then
immunostained with HLN5 MoAb conjugated with peroxidase.
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expectation, serum laminin values in 84 cancer patients did
not correlate with their ULN values. This result indicated
that elevation of ULN level was not accompanied by eleva-
tion of serum laminin levels. Serum laminin and ULN, pos-
sibly secreted by distinct mechanisms, may therefore provide
different information regarding malignant status in cancer
patients. Some reports have already demonstrated that
diabetic rats showed increased levels of serum laminin
(Risteli et al., 1982). However, the distribution of ULN levels
in diabetes patients was the same as in healthy subjects
(Figure 4).
This is the first study in which ULN fragments were
immunopurified and analysed biolochemically. The 13
sequences of N-terminal 15 residues of isolated ULN were
identical to that around the N-terminal end of human
laminin B2 chain deduced from the nucleotide sequence, as
reported previously (Pikkarainen et al., 1988). The result of
computer homology search using the EMBL data bank
indicates that obtained sequences of ULN fragment is appar-
ently derived from laminin, not from other unrelated protein.
The apparent molecular mass of immunostained ULN
antigen on the transblotted membrane was about 42 KD
under non-reducing condition (Figure 5). Thus, ULN was
apparently constituted of about 450 amino acids residues.
These data enable us to conclude that ULN antigen basically
comprises domain V and VI of laminin B2 chain, and that
HLN5 and HLN82 MoAbs specifically react with these
domains. HLN41 MoAb appeared to bind somewhere on
intact laminin molecule, but failed to react with this ULN
fragments and P1 fragment of laminin which comprises the
inner region of the cross molecule. It appears therefore that
HLN41 MoAb is recognising the other terminal domain of
laminin molecule. The schematic representation of the
domain structure of laminin and the binding epitopes of
HLN5 and HLN82 MoAbs, which recognise the domain V
or VI, are shown in Figure 6. The antigenic determinant
recognised by HLN41 MoAb has not been well defined in
this study and the location of its epitope cannot therefore be
shown.
We speculated on the possible reasons why N-terminal
domains of laminin B2 chain were excreted in urine samples
and were increased in cancer patients, as follows: A previous
report indicated that less laminin is present in basement
membrane structures associated with metastatic tumours
compared with non-metastatic or benign lesions (Albrechtsen
et al., 1981). A compromised basement membrane may be a
consequence of increased turnover of such components as
laminin and type IV collagen, or alternatively, it may be a
result of decreased synthesis. The former possibility was con-
sidered in this study, since there is abundant evidence
documenting the elevated expression of various proteases in
separate tumour tissues and the proteolytic degradation of
laminin in the extracellular matrix (Jones & De Clerck, 1982;
Boyd et al., 1989). The extracellular matrix components de-
graded by tumour cells were thought to be released first from
primary sites, second to be circulated in blood flow, and
finally to be excreted into urine through the kidney.
Computer analysis revealed that the Bl and B2 chains of
laminin are highly homologous proteins which are probably
the products of related genes (Pikkarainen et al., 1988).
However, some extra domains of the laminin B1 chain have
no counterpart in B2, and the number of cysteine-rich
repeats is 12, or one less than in the Bl chain. The degree of
homology between the two chains is highest in the cysteine
repeat-containing domains III, V, and VI, where 40% of the
residue matches. On the contrary, the degree of complete
matches between the globular domain IV and the Bl and B2
chain is only 28%, and then it was interesting that the B2
chain contains no cysteine residue in this region, whereas the
Bl chain has five. It can be assumed that domain IV of B2
chain with no cystein residues is potentially sensitive to pro-
tease attack by tumour cells and tends to be destroyed
around a primary or metastatic tumour site.
Previous reports showed that ULN in rats with experi-
mental nephrosis could be measrued by RIA for laminin P2
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Figure 6 Stucture model of laminin and the binding sites of
MoAbs used in IEMAs for ULN fragments. Globular regions in
the A, Bi, and B2 chain are indicated by patched circles. Desig-
nations ofdomains by roman numerals is according to a previous
report (Beck et al., 1990). ULN fragment is interpreted as
domain V and VI in B2 chain, and the epitopes of HLN5 MoAb
and HLN82 MoAb are recognised to exist within these regions.
fragments, which are suggested to contain the terminal por-
tion of laminin molecules (Jukkola et al., 1985). Laminin P2
fragments, isolated from limited-pepsin digestions ofplacenta
or intact laminin, were reported to have a molecular mass of
about 45 KD (Rohde et al., 1980). ULN fragments charac-
terised in this study, which basically consisted of N-terminal
domain of the B2 chain, may have similar antigenicity to P2
fragments.
Many urinary tumour markers have been investigated
previously (Kardana et al., 1988; Mattila et al., 1988;
Katayama et al., 1991). Fibronectin (FN), major extracellular
matrix components with a high molecular mass, is a very
popular cell adhesive glycoprotein as well as laminin and
collagens (Hynes & Yamada, 1982). Recently we and our
collaborators demonstrated that urinary FN fragments also
significantly increase in almost all kinds of tumours including
stomach, lung, liver, colon, and others (Katayama et al.,
1991). When extracellular matrix containing the cell adhesive
proteins is degraded around tumours, these proteins may be
fragmented by proteases secreted from tumours. However,
the distribution of FN in tissue and body fluid was reported
to be slightly different from that of laminin (Beck et al.,
1990). Previous immunofluorescence studies have suggested
that laminin is an abundant component of basement mem-
brane and ultrastructural studies have localised laminin to
the lamina rara of epidermal and glomerular basement mem-
branes (Timpl et al., 1982). Plasma concentration of FN,
reported to be 300jig ml-', is significantly different from that
of laminin which was reported to be about 30 ng ml-'
(Hynes et al., 1982; Risteli et al., 1982). The elevation of
urinary FN levels in various kinds of tumours appears to
result from widespread distribution of FN in tissue and body
fluid. On the contrary, increased ULN levels are possible to
be observed in specified kinds of tumours, because laminin
may be localised mostly in tissues and organs containing
large amount of basement membrane. We have shown that
ULN levels in lung tumours were significantly elevated com-
pared to those in the other tumours. Increased ULN detected
only in lung tumours is, however, difficult to explain. It is
well known that extracellular matrix components, laminin or
FN, secreted by several cultured human cells may be involved
in cell-binding to these adhesive matrix proteins. Various514 M. KATAYAMA et al.
kinds of cells are producing cellular FN. It is very interesting
that a detectable amount of laminin can be secreted only by
cultured human cell lines from fibrosarcoma, osteosarcoma,
or lung tumour (unpublished observation). We are intending
to study the correlation between ULN level in the cancer
patients and the amount of laminin present in the tumour
tissue. In future, this study may clarify the mechanism of
elevated ULN excretion in lung tumours.
In preliminary studies, it was observed that ULN levels did
not always correlate with urinary FN in cancer patients
(unpublished observation), therefore, we expected that a
combination assay to measure both laminin fragments and
FN fragments in urine would provide a more specific and
sensitive diagnostic system for malignancy. Hence, ULN may
be used as a diagnostic marker not only for lung tumours,
but also for other malignancies which degrade the basement
membrane components.
We describe here a new urinary tumour marker which we
have fQund to be superior to other markers in simplicity,
speed, and noninvasiveness of its assay. These results suggest
that this assay will be prospectively useful in tumour diag-
nosis, especially in screening groups of patients undergoing
physical checkups and in monitoring cancer patients.
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